Highly efficacious 5-way protection
for time-saving convenience.

Broad protection against:

• Eastern Encephalomyelitis
• Western Encephalomyelitis
• Rhinopneumonitis Respiratory (EHV-1 & EHV-4)
• Equine Influenza Virus, including KY 93
• Tetanus Toxoid

Formulated to minimize reactions and maximize protection:

• Intervet’s Antigen Purification System (APSTM) filtration technology removes extraneous viruses, cellular debris and foreign protein to reduce post-vaccinal reactions
• Precise titration of antigen levels maintain the critical “antigen mass” to achieve protective immunity
• Low-volume, 1 mL dose

Unique Havlogen® adjuvant:

• Intervet’s proprietary adjuvant technology
• Maintains uniform suspension for consistency and potency – doesn’t settle out
• Stimulates both cell-mediated (T-cells) and humoral (B-cells) immune responses
• Produces a booster effect, stimulating higher, longer-lasting protection through the slow release of antigens

DESCRIPTION: A combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Equine Encephalomyelitis Virus, Eastern and Western, Equine Herpesvirus EHV-1 and EHV-4, Equine Influenza Virus subtype A2 including KY 93 strain and Tetanus Toxoid. Intervet serological data suggest influenza cross protection against certain U.S. and European strains, including Kentucky 93, 94, 95 and 96, Suffolk 89, Kildare 89 and 92, Austria 92, Switzerland 93, New Market 1/93 and 2/93, Berlin 94, Italy 96 and Meath 96.

INDICATIONS: For vaccination of healthy horses as an aid in the prevention of Eastern and Western Encephalomyelitis, Equine Influenza Virus and Tetanus, and as an aid in the control of respiratory disease caused by Equine Herpesvirus.

ADMINISTRATION AND DOSAGE: For primary immunization, aseptically inject 1 mL intramuscularly and repeat the dose in 3 to 4 weeks. A 1 mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.

CAUTION: Store at 35o to 45o F (2o to 7o C). Shake well before using. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

ANTIDOTE: Epinephrine.
Neomycin, polymyxin B, nystatin and thimerosal added as preservatives.

SUPPLIED:
Code: E-995-1 10 x 1 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.
E-995-10 10 mL (10 doses) vial.

FOR USE IN ANIMALS ONLY
*Adjuvant – Intervet’s proprietary technology.

Six-way protection and time-saving convenience.
Protective immunity in a low-volume, 1ml dose.

Encephalomyelitis-Rhinopneumonitis-Influenza Vaccine, Eastern, Western and Venezuelan Equine Encephalomyelitis (Sleeping Sickness) and Tetanus Toxoid

Description: A combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Equine Encephalomyelitis Virus, Eastern, Western, and Venezuelan, Equine Herpesvirus EHV-1 and EHV-4, Equine Influenza Virus subtypes A2 including KY 93 strain and Tetanus Toxoid. Intervet serological data suggest Influenza cross protection against certain U.S. and European strains, including Kentucky 93, 94, 95 and 96, Suffolk 89, Kildare 89 and 92, Austria 92, Switzerland 93, New Market 1/93 and 2/93, Berlin 94, Italy 96 and Meath 96.

Indications: For vaccination of healthy horses as an aid in the prevention of Eastern, Western and Venezuelan Encephalomyelitis, Equine Influenza Virus and Tetanus, and as an aid in the control of respiratory disease caused by Equine Herpesvirus.

Administration and dosage:  For primary immunization, aseptically inject 1 mL intramuscularly and repeat the dose in 3 to 4 weeks. A 1 mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.

Caution: Store at 35^o to 45^o F (2^o to 7^oC). Shake well before using. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

Antidote: Epinephrine. Neomycin, polymyxin B, nystatin and thimerosal added as preservatives.

Supplied:
Code: 006862
10 X 1 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.
Code: 006861
10 mL (10 doses) vial.

The veterinarian’s choice for EHV-1
and EHV-4 respiratory protection.

For EHV-1 and EHV-4, the clear choice is both...in Prestige® vaccines.

• The origination and development of a disease caused by EHV-1 and EHV-4 can be different.
• EHV-4 is more commonly associated with respiratory disease than is EHV-1.

 
Formulated to minimize reactions and maximize protection.

• Protection against both EHV-1 and EHV-4.
• Tissue culture origin, not egg protein.

Prestige® II protects against influenza.

• Equine influenza subtype A2, including KY 93 strain.
• Cross-protection against certain U.S. and European strains, including Kentucky 93, 94, 95 and 96; Suffolk 89; Kildare 89 and 92; Austria 92; Switzerland 93; New Market 1/93 and 2/93; Berlin 94; Italy 96; and Meath 96.

Unique Havlogen® adjuvant.

• Intervet’s proprietary adjuvant technology.
• Maintains uniform suspension for consistency and potency in each dose – doesn’t settle out.
• Stimulates both cell-mediated (T-cells) and humoral (B-cells) immune response.
• Produces a booster effect stimulating higher, longer-lasting protection through the slow release of antigens.

DESCRIPTION: A combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin Equine Herpesvirus EHV-1 and EHV-4 and Equine Influenza Virus subtype A2 including KY 93 strain. Intervet serological data suggest cross protection against certain U.S. and European strains, including Kentucky 93, 94, 95 and 96; Suffolk 89; Kildare 89 and 92; Austria 92; Switzerland 93; New Market 1/93 and 2/93; Berlin 94; Italy 96; and Meath 96.

INDICATIONS: For vaccination of healthy horses as an aid in the prevention of respiratory disease caused by Equine Herpesvirus and Equine Influenza Virus.

DOSE: For primary immunization, aseptically inject 1 mL intramuscularly and repeat the dose in 4 to 6 weeks. A 1 mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.

CAUTION: Store at 35º F to 45º F (2º C to 7º C). Shake well before using. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

ANTIDOTE: Epinephrine.
Neomycin, polymyxin B, nystatin and thimerosal added as preservatives.

SUPPLIED:
Code: E-994-1 10 X 1 mL (1 dose)
sterile syringes per box, individually printed plastic bag with needle.
E-994-10 10 mL (10 doses) vial.

FOR USE IN ANIMALS ONLY
*Adjuvant – Intervet’s proprietary technology.

Equine Rhinopneumonitis Vaccine

Description: A combination of inactivated, purified, concentrated, adjuvanted, equine tissue culture origin Equine Herpesvirus EHV-1 and EHV-4.

Indications: For vaccination of healthy horses against respiratory diseases caused by Equine Herpesvirus.

Administration and dosage: For primary immunization, aseptically inject 1 mL intramuscularly. Repeat the dose in 4 to 6 weeks. A 1 mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.

Caution: Store at 35o to 45o F (2o to 7oC). Shake well before using. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

Antidote: Epinephrine. Neomycin, polymyxin B, nystatin and thimerosal added as preservatives.

Supplied:

Code: E-663-1
10 X 1 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.

Code: E-663-10
10 mL (10 doses) vial.